Circulating Tumor DNA Clinical Trial
Official title:
Circulating Tumor DNA as a Novel Molecular Marker of Treatment Efficacy to Guide Targeted Maintenance Therapy for Patients With High Grade Serous Ovarian Cancer
NCT number | NCT05027828 |
Other study ID # | XH-21-008 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | May 1, 2024 |
Est. completion date | September 30, 2024 |
Verified date | April 2023 |
Source | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study is a prospective observational clinical trial. Patients who were diagnosed and treated for the first time were enrolled and their surgical pathology was confirmed to be high-grade serous ovarian cancer. At the same time, these patients will receive first-line maintenance treatment with PARP inhibitors after traditional chemotherapy. During the trial period, patients' plasma will be collected before surgery, after chemotherapy, during targeted maintenance therapy, and during disease progression, and ctDNA-specific genomes will be detected, and clinical data will be collected over the same period. It is expected that specific ctDNA can be used to predict the efficacy of PARP inhibitors in patients with ovarian cancer, and to detect the recurrence of the disease early.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | September 30, 2024 |
Est. primary completion date | August 30, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Ovarian cancer first diagnosed and treated; 2. Pathologically confirmed as epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer; 3. The stage of the disease is II-IV, and surgery will be performed after evaluation; 4. Age = 18 years old; 5. Subjects and their families fully understand the research plan and sign an informed consent form. Exclusion Criteria: 1. Pathologically confirmed as non-epithelial ovarian cancer; 2. Surgical treatment cannot be performed after evaluation; 3. Malignant tumors found in other parts of the study were found within five years before enrollment or at the time of enrollment; 4. Patients who do not agree to use clinical first-line targeted drugs; 5. Severe mental illness; 6. Severe cardiovascular disease, uncontrollable infection, or other uncontrollable comorbid diseases. |
Country | Name | City | State |
---|---|---|---|
China | Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival | To determine the different prognosis of patients after using the PARP inhibitor for first-line maintenance treatment, at the same time, the plasma will be collected and tested for ctDNA before using the PARP inhibitor, during use and when the disease is progressing. | about 36 months after using PARP inhibitors | |
Secondary | Overall survival | about over 5 years after using PARP inhibitors | ||
Secondary | Objective response rate | To evaluate the general response of patients with ovarian cancer to PARP inhibitors | 36 months after using PARP inhibitors |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05167604 -
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
|
||
Recruiting |
NCT05598528 -
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
|
||
Recruiting |
NCT04555369 -
The Value of ctDNA on Chemotherapy Efficacy for mCRC
|
N/A | |
Not yet recruiting |
NCT03688035 -
Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
|
||
Recruiting |
NCT03737539 -
Dynamic Monitoring of ctDNA Methylation to Predict Relapse in Colorectal Cancer After Radical Resection (POSTCA)
|
||
Not yet recruiting |
NCT04511559 -
Methylation Analysis of Circulating Tumor DNA in Gastric Cancer
|
||
Recruiting |
NCT03748680 -
IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer
|
Phase 2 | |
Completed |
NCT02620527 -
Concordance Between ctDNA Assay and FoundationOne
|
||
Recruiting |
NCT05529615 -
Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer
|
N/A | |
Recruiting |
NCT05601505 -
Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer
|
Phase 2 | |
Recruiting |
NCT05161585 -
Evaluation of Circulating Tumor DNA Guided Surveillance Strategy of Stage III Colorectal Cancer: an Open, Prospective, Randomized Controlled Cohort Study
|
N/A | |
Recruiting |
NCT05390112 -
Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization
|
||
Recruiting |
NCT06434896 -
Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial
|
N/A | |
Recruiting |
NCT04966663 -
Using ctDNA to Determine Therapies for Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05801263 -
ctDNA Methylation for Epithelial Ovarian Cancer
|
||
Recruiting |
NCT05801276 -
ctDNA Methylation for Detecting Ovarian Cancer
|
||
Active, not recruiting |
NCT04276337 -
Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy
|
||
Recruiting |
NCT05969938 -
Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology
|
||
Completed |
NCT04456972 -
Reliability and Interest of Circulating Tumor DNA in Endometrial Cancers.
|
N/A | |
Completed |
NCT06404593 -
Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases
|